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Elevated fatty acids promote inflammation and insulin resistance. In this issue ofCell Metabolism, Koves et al.
(2008) explore a novel paradigm suggesting that b-oxidation of fatty acids exceeding the capacity of the
tricarboxylic acid cycle yields incomplete fat oxidation and mitochondrial distress, obligatory events in the
pathogenesis of insulin resistance.High-fat feeding and elevation in circulat-
ing fatty acid levels caused by triglyceride
and heparin infusion are known to cause
skeletalmuscle insulin resistance. Despite
decades of intense investigation, the pre-
cise signaling events that underlie fatty
acid-induced insulin resistance remain in-
completely defined. It is currently held that
excessive fatty acid uptake into the myo-
cyte and reduced fat oxidation lead to
the accumulation of proinflammatory lipid
metabolites such as fatty acyl-CoAs, diac-
ylglycerol, and ceramide. These metabo-
lites activate serine/threonine ‘‘stress’’
kinases including c-jun N-terminal kinase
(JNK), IKKb, and PKCq, which in turn pro-
mote inflammatory signaling and antago-
nize insulin action (Wellen and Hotamisli-
gil, 2005) (Figure 1). Reduced expression
of carnitine palmitoyltransferase 1 (CPT1),
the rate-limiting enzyme for fatty acidentry
into the mitochondria, and impaired mito-
chondrial function (decreased mitochon-
drial number, lower levels of oxidative en-
zymes, and lower ATP synthetic rates) are
found in insulin-resistant skeletal muscle
and coincide with muscle lipid accumula-
tion (Befroy et al., 2007; Kim et al., 2000;
Petersen et al., 2004; Ritov et al., 2005).
In the current issue, Koves et al. (2008)
provide evidence supporting a novel met-
abolic link between fatty acid oversupply
and insulin resistance in skeletal muscle.
In contrast to the widely accepted view
that mitochondrial fatty acid entry and
b-oxidation are reduced in insulin resis-
tance, Koves et al. (2008) suggest that
when the rate ofmitochondrial b-oxidation
is elevated and exceeds flux through the
tricarboxylic acid (TCA) cycle and electron
transport chain (ETC), incomplete fatty
acid oxidation occurs, leading to intra-
mitochondrial metabolite accumulation,mitochondrial stress, and cellular insulin
resistance. Furthermore, their work sup-
ports the notion that entry of fatty acids
into the mitochondria is compulsory to
achieve cellular insulin resistance.
One central regulatory enzyme control-
ling fatty acid flux and b-oxidation (Dob-
bins et al., 2001) is CPT1, located in the
outer mitochondrial membrane. In close
proximity is acetyl-CoA carboxylase
(ACC), a cytosolic enzyme that catalyzes
the carboxylation of cytosolic acetyl-CoA
to form malonyl-CoA, a potent inhibitor of
CPT1 and thus a key metabolic regulator
of fatty acid oxidation (Figure 1). Ma-
lonyl-CoA levels are controlled by the rel-
ative activities of ACC and malonyl-CoA
decarboxylase (MCD), the principal en-
zyme involved in malonyl-CoA degra-
dation. When malonyl-CoA levels rise,
mitochondrial fatty acid import and oxida-
tion are suppressed, and this favors fatty
acid storage in the form of triglyceride.
ACC inhibition, CPT1 activation, and en-
hanced fatty acid oxidation have previ-
ously been shown to be associated with
insulin sensitivity and protection against
diet-induced insulin resistance (Choi
et al., 2007; Dobbins et al., 2001; Petersen
et al., 2004; Ritov et al., 2005).
Koves et al. (2008) use dietary, pharma-
cologic, and genetic perturbations to de-
termine the effects of lipid excess on fatty
acid oxidation, relying heavily on themea-
surement of acylcarnitine (Van Hove et al.,
1993) and acid-soluble metabolite (ASM)
concentration as surrogate indices of
b-oxidation and incomplete fat oxidation,
respectively. Several acylcarnitine spe-
cieswere found to be elevated and a trend
toward lower organic acid (lactate, citrate,
malate, and succinate) levels was ob-
served in muscle from high-fat (HF)-fedCell Metaband genetically obese Zucker diabetic
fatty rats, suggesting that mitochondrial
fatty acid uptake and b-oxidation ex-
ceeded TCA cycle flux. Additional studies
performed in crude homogenates and
isolated mitochondria extracted from
gastrocnemius muscle showed that while
mitochondria from HF-fed rats displayed
similar rates of complete fatty acid oxida-
tion compared to mitochondria from lean
rats, they accumulatedmore acylcarnitine
and ASMs, reflective of incomplete fatty
acid oxidation. Interestingly, while the ad-
dition of pyruvate to these preparations
caused a robust inhibition of fatty acid
oxidation in mitochondria from normal
chow-fed rats, mitochondria from HF-fed
rats were unresponsive to pyruvate,
which implies impaired substrate shifting
from fat to carbohydrate metabolism, an
observation consistent with the concept
of metabolic inflexibility.
To assess whether excessive b-oxida-
tion is critical for the development of
lipid-induced insulin resistance in cultured
rat myotubes, either carnitine or etomoxir
(a potent CPT1 inhibitor) was added to
the culture medium to enhance or inhibit
flux through the b-oxidative pathway
(Figure 1). Inhibiting flux through CPT1
prevented acylcarnitine accumulation
and protected myotubes against fat-
induced insulin resistance, while the ad-
dition of carnitine to the medium was
mandatory for fatty acid-induced insulin
resistance. This observation is somewhat
surprising in light of findings from many
laboratories demonstrating impaired insu-
lin action in culturedmyotubes exposed to
either saturated or unsaturated long-chain
fatty acids in the absence of carnitine (Per-
domo et al., 2004). Moreover, previous
studies indicate that etomoxir treatmentolism 7, January 2008 ª2008 Elsevier Inc. 5
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PreviewsFigure 1. Incomplete Fat Oxidation Causes Mitochondrial Stress and Mediates Skeletal
Muscle Insulin Resistance
Circulating fatty acids cross the plasma membrane into the myocyte by diffusion or protein-mediated
transport and are either stored as triacylglycerol (TAG) or transported into the mitochondria by carnitine
palmitoyltransferase 1 (CPT1). Chronic high-fat feeding and/or genetic obesity cause elevated rates of
b-oxidation that exceed the capacity of the tricarboxylic acid (TCA) cycle and electron transport chain
(ETC); this results in incomplete fat oxidation and accumulation of acylcarnitines within the mitochondria.
These events elicit an unknownmitochondria-derived stress signal (labeled ‘‘?’’) that is obligatory for skel-
etal muscle insulin resistance. Inhibition of CPT1 and b-oxidation by etomoxir treatment or mcd deletion
([ malonyl-CoA levels) prevents incomplete fat oxidation and mitochondrial acylcarnitine buildup and
protects against fatty acid-induced insulin resistance.in rats exacerbates fatty acid-induced insu-
lin resistance (Dobbins et al., 2001) while
CPT1 overexpression in myotubes (Sebas-
tian et al., 2007) or enhanced b-oxidation
in mice harboring an acc2 null mutation
(Choi et al., 2007) is protective.
Next, the effect of CPT1 inhibition on in
vivo insulin sensitivity was tested by
studying mice harboring a whole-body
malonyl-CoA desaturase (mcd) null muta-
tion (KO). MCD degrades malonyl-CoA
and relieves inhibition of CPT1, which fa-
cilitates fatty acid flux into the mitochon-
dria (Figure 1). Deletion of mcd markedly
elevated malonyl-CoA levels, although
acylcarnitine intermediates and insulin
sensitivity were not different in mcd KO
versus WT animals fed a normal chow
diet. When animals were fed a HF diet,
mcd deletion prevented the accumulation6 Cell Metabolism 7, January 2008 ª2008 Eof most acylcarnitine species (i.e., incom-
plete b-oxidation) in muscle and protected
animals fromglucose intolerance and insu-
lin resistance. This finding is contrary to
previous results obtained in acc2 null
mice, wherein enhanced b-oxidation con-
ferred protection against fat-induced insu-
lin resistance (Choi et al., 2007).
The work by Koves et al. (2008) pro-
vides a novel link between impaired
mitochondrial function and insulin ac-
tion; however, more detailed studies are
needed to show precisely how acylcarni-
tine accumulation and other products of
incomplete fatty acid oxidation are related
or causal in the genesis of insulin resis-
tance. Equally important is experimental
support for the hypothesis that limiting
fat metabolism in muscle may prevent or
ameliorate insulin resistance when inter-lsevier Inc.ventions aimed at enhancing fat break-
down by muscle are well supported. In
this regard, the clinical efficacy of b-oxi-
dation inhibition in the treatment of type
2 diabetes has yet to be tested. An alter-
native clinical approach substantiated by
the same group (Koves et al., 2005) ad-
vocates therapies promoting increased
TCA cycle capacity and flux as occurs
with endurance exercise training or ex-
perimentally with PGC-1a overexpres-
sion. To flux or not to flux the mitochon-
dria, that is the question.
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